RE:A backhanded 20-fold target population estimate/concern....Right on! This is great news, even better than becoming an Orphan Status drug which is under 200000 patients. FDA expects them to treat more than 200000 patients, or else would have granted OS. They must see this drug as a step up above BCG, or at least an alternate choice with superior results. IMHO